<DOC>
	<DOC>NCT02256722</DOC>
	<brief_summary>Study to compare the metabolic and electrolyte effects of a single oral dose of 320 mg ritobegron administered alone or with a pre- and comedication with bisoprolol, propranolol and acipimox. In addition, to compare the metabolic and electrolyte effects of a single dose of 320 mg ritobegron with those of a single inhalatory dose of 100 Î¼g salmeterol</brief_summary>
	<brief_title>In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>p-Hydroxyamphetamine</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Healthy male Age &gt;= 30 and &lt;= 60 years Body Mass Index (BMI) &gt;= 18.5 and &lt;= 29.9 kg/m2 Signed and dated written informed consent in accordance with Good Clinical Practice and local legislation Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, clinically relevant electrolyte disturbances Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or clinically relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24:00 hours) within at least one month or less than ten halflives of the respective drug before enrolment in the study or during the study Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study Participation in another trial with an investigational drug (within two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars of &gt; 3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (&gt; 100 mL within four weeks prior to administration or during the trial) Any laboratory value outside the reference range if indicative of underlying disease or poor health Excessive physical activities within the last week before the trial or during the trial Hypersensitivity to treatment medication, salmeterol and/or related drugs of these classes Congenital or documented acquired QT prolongation, previous history of symptomatic arrhythmias Systolic BP &lt; 115 mmHg Heart rate at rest of &gt; 80 bpm or &lt; 55 bpm Any screening ECG value outside of the reference range of clinical relevance including, but not limited to PR interval &gt; 220 ms, QRS interval &gt; 115 ms, QTcB &gt; 420 ms, or QT (uncorrected) &gt; 450 ms History of asthma or obstructive pulmonary disease. Psoriasis (own medical history or relative)</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>